



## ORIGINALS

Bilingual edition English/Spanish

## PAUSATE Study: Prevalence and appropriateness of the use of antimicrobials in Spanish hospitals

### Estudio PAUSATE: Prevalencia y adecuación del uso hospitalario de antimicrobianos en España

José María Gutiérrez-Urbón<sup>1</sup>, Mercedes Arenere-Mendoza<sup>2</sup>,  
Eduarne Fernández-de-Gamarra-Martínez<sup>3</sup>, Aurora Fernández-Polo<sup>4</sup>,  
Silvia González-Suárez<sup>5</sup>, Jordi Nicolás-Picó<sup>6</sup>, María Eugenia Rodríguez-Mateos<sup>7</sup>,  
Elena Sánchez-Yáñez<sup>8</sup>

<sup>1</sup>Pharmacy Department. Complejo Hospitalario Universitario A Coruña. Spain. <sup>2</sup>Pharmacy Department. Hospital Clínico Universitario Lozano Blesa. Zaragoza. Spain. <sup>3</sup>Pharmacy Department. Hospital de la Santa Creu i San Pau. Barcelona. Spain. <sup>4</sup>Pharmacy Department. Hospital Universitari Vall d'Hebron. Barcelona. Spain. <sup>5</sup>Pharmacy Department. Hospital Universitario Nuestra Señora de Candelaria. Santa Cruz de Tenerife. Spain. <sup>6</sup>Pharmacy Department. Hospital Universitari Mútua Terrassa, Barcelona. Spain. <sup>7</sup>Pharmacy Department. Hospital Universitario Puerto del Mar. Cádiz. Spain. <sup>8</sup>Pharmacy Department. Hospital Universitario Virgen de la Victoria. Málaga. Spain.

## Author of correspondence

José María Gutiérrez Urbón  
Avenida As Xubias, 84.  
15006 La Coruña. Spain.

Email:

Jose.Gutierrez.Urbon@sergas.es

Received 17 November 2021;  
Accepted 17 January 2022.  
Early Access date (08/02/2022).  
DOI: 10.7399/fh.13152

## How to cite this paper

Gutiérrez-Urbón JM, Arenere-Mendoza M, Fernández-de-Gamarra-Martínez E, Fernández-Polo A, González-Suárez S, Nicolás-Picó J, Rodríguez-Mateos ME, Sánchez-Yáñez E. PAUSATE Study: Prevalence and appropriateness of the use of antimicrobials in Spanish hospitals. Farm Hosp. 2022;46(5):271-81.

## Abstract

**Objective:** To determine the prevalence and appropriateness of antimicrobial use in Spanish hospitals through a pharmacist-led systematic cross-sectional review.

**Method:** A nationwide multicenter cross-sectional study was conducted on 10% of the patients admitted to the participating hospitals on one day in April 2021. Hospital participation was voluntary, and the population was randomly selected. The study sample was made up of patients who, on the day of the study, received at least one antimicrobial belonging to groups J01, J02, J04, J05AB, J05AD or J05AH in the Anatomical Therapeutic Chemical Classification System. The pharmacist in charge made a record and carried out an evaluation of the appropriateness of antimicrobial use following a method proposed and validated by the Pharmaceutical Care of Patients with Infectious Diseases Working Group of the Spanish Society of Hospital Pharmacy. The evaluation method considered each of the items comprising antimicrobial prescriptions. An algorithm was used to assess prescriptions as appropriate, suboptimal, inappropriate and unevaluable.

## KEYWORDS

Antimicrobial stewardship; Quality indicators healthcare; Cross-sectional studies; Drug utilization; Anti-infective agents.

## PALABRAS CLAVE

Programas de optimización del uso de antimicrobianos; Indicadores de calidad de la atención de la salud; Estudios transversales; Utilización de medicamentos; Antiinfecciosos.

## Resumen

**Objetivo:** Conocer la prevalencia y el grado de adecuación del uso de antimicrobianos en los hospitales españoles mediante una revisión sistemática transversal realizada por farmacéuticos.

**Método:** Estudio multicéntrico, nacional, transversal sobre el 10% de los pacientes ingresados en los hospitales participantes un día del mes de abril de 2021. La participación de los hospitales fue voluntaria y la selección de la población aleatoria. De la población se disgregó la muestra de estudio, constituida por los pacientes que recibían el día del corte al menos un antimicrobiano perteneciente a los grupos J01, J02, J04, J05AB, J05AD y J05AH del Sistema de Clasificación Anatómica, Terapéutica y Química. Sobre la muestra de estudio, el farmacéutico realizó un registro y evaluación de la adecuación del tratamiento antimicrobiano siguiendo una metodología propuesta y validada por el Grupo de trabajo de Atención Farmacéutica al Paciente con Enfermedad Infecciosa de la Sociedad Española de Farmacia Hospitalaria. La metodología de evaluación consideró cada una de las dimensiones que conforman la prescripción del antimicrobiano e incluyó un algoritmo para calificar la prescripción global como adecuada, mejorable, inadecuada y no valorable.



Los artículos publicados en esta revista se distribuyen con la licencia  
Articles published in this journal are licensed with a  
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.  
<http://creativecommons.org/licenses/by-nc-sa/4.0/>  
La revista Farmacia no cobra tasas por el envío de trabajos,  
ni tampoco por la publicación de sus artículos.

**Results:** One-hundred three hospitals participated in the study and the treatment of 3,568 patients was reviewed. A total of 1,498 (42.0%) patients received antimicrobial therapy, 424 (28.3%) of them in combination therapy. The most commonly prescribed antimicrobials were amoxicillin-clavulanic acid (7.2%), ceftriaxone (6.4%), piperacillin-tazobactam (5.8%), and meropenem 4.0%. As regards appropriateness, prescriptions were considered appropriate in 34% of cases, suboptimal in 45%, inappropriate in 19% and unevaluable in 2%. The items that most influenced the assessment of a prescription as suboptimal were completeness of medical record entries, choice of agent, duration of treatment and monitoring of efficacy and safety. The item that most influences the assessment of a prescription as inappropriate was the indication of antimicrobial agent.

**Conclusions:** The method used provided information on the prevalence and appropriateness of the use of antimicrobials, a preliminary step in the design and implementation of actions aimed at measuring the impact of the use of antimicrobials within the antimicrobial stewardship programs.

**Resultados:** Participaron 103 hospitales y se revisó el tratamiento de 3.568 pacientes, de los que 1.498 (42,0%) recibieron terapia antimicrobiana, 424 (28,3%) en combinación. La prevalencia de los antimicrobianos más frecuentes fue: amoxicilina-clavulánico 7,2%, ceftriaxona 6,4%, piperacilina-tazobactam 5,8% y meropenem 4,0%. Respecto a la adecuación del tratamiento la prescripción, fue considerada adecuada en el 34% de los casos, mejorable en el 45%, inadecuada en el 19% y no valorable en el 2%. Las dimensiones que más influyeron en la calificación de la prescripción como mejorable fueron el registro en la historia clínica, la elección del agente, la duración del tratamiento y la monitorización de la eficacia y seguridad, y como inadecuada la indicación de antimicrobiano.

**Conclusiones:** La metódica utilizada permite conocer la prevalencia y adecuación del uso de antimicrobianos, paso previo para diseñar y emprender acciones de mejora y medir el impacto de su implantación en el marco de los programas de optimización del uso de antimicrobianos.

## Introduction

Inappropriate use of antimicrobials is, to a greater or lesser extent, an undeniable reality in any hospital. However, the degree to which such drugs are inappropriately used is difficult to quantify due to the methodological and practical difficulties inherent in its measurements and the lack of standardized evaluation methods. Various studies in different countries have estimated inappropriate use of antimicrobials in hospitals at levels ranging between 16 and 70%<sup>1-4</sup>. The consequences of the inappropriate use of antimicrobials include an increased risk of adverse events such as *Clostridioides difficile* infection, therapeutic failure with potential effects on morbidity and mortality, selection of resistant microorganisms, and increased health costs<sup>5-7</sup>.

A particularly relevant phenomenon is the increase observed in bacterial resistance to antimicrobials, which has become a global health problem. The World Health Organization has set the antimicrobial stewardship as one of the five strategic goals in the fight against microbial resistance<sup>8</sup>.

Antimicrobial stewardship programs (ASPs) are being progressively implemented in Spanish hospitals. Their goals include improving clinical outcomes, minimizing adverse events, including resistance, and measuring and improving the appropriate use of antimicrobial agents to ensure the cost-effectiveness of treatments<sup>9,10</sup>.

Various strategies have been proposed to estimate the quality of antimicrobial use in different settings. One of them consists in establishing quality of use indicators based on consumption<sup>11,12</sup>. However, the most commonly used method for assessing the prevalence and use of antimicrobials is the performance of cross-sectional studies<sup>1,13,14</sup>. These are usually carried out in a single day and are an efficient tool when time and resources do not allow for a longitudinal study. A significant sample can provide information on the prescription of antibiotics at different times in the course of treatment. In Spain, the National Epidemiological Surveillance Network (RENAVE) annually records the prevalence of antimicrobial use in hospitals<sup>15</sup>.

The evaluation of antimicrobial drug prescriptions should consider several items such as indication, spectrum, dosage, duration, efficacy and safety monitoring, and registration. The biggest problem about performing a systematic evaluation of antimicrobial prescription is the difficulties in using a standardized method due to the complexities inherent in the evaluation of each of these items. Another critical point is the fraction of subjectivity in the evaluation that leads to inter-observer variability<sup>16-18</sup>.

The aim of the PAUSATE study was to evaluate the prevalence and degree of appropriateness of antimicrobial use in Spanish hospitals by means of a pharmacist-led cross-sectional systematic review.

## Methods

### Study design

This was a nationwide multicenter cross-sectional study that analyzed 10% of the patients admitted to the participating hospitals on one day in April 2021. This percentage was chosen to avoid an excessive workload

in larger hospitals and to encourage mass participation. Participation in the study was voluntary and channeled through the mailing list of the Spanish Society of Hospital Pharmacists (SEFH). Each hospital was required to nominate a research pharmacist. Optionally, other pharmacists could also participate to help with data collection, but the actual evaluations were the responsibility of the research pharmacist.

The research pharmacist at each center chose a day within the study period to perform the prevalence cutoff. The study population was chosen by randomly selecting 10% of the patients admitted on the cutoff day, without excluding any clinical services. The randomization method was freely chosen by each hospital, although instructions were provided to do this using an Excel spreadsheet.

The study sample drawn from randomized patients and consisted of individuals receiving at least one antimicrobial on the day of the cutoff. The agents belonging to the following groups under the Anatomical, Therapeutic and Chemical Classification System (ATC)<sup>19</sup>: J01 (systemic antibacterials), J02 (systemic antifungal agents), J04 (antimycobacterials), J05AB (direct-acting nucleotide/nucleoside analogs, excluding reverse transcriptase inhibitors), J05AD (direct acting phosphonic acid derivative antivirals) and J05AH (direct acting neuraminidase inhibitor antivirals).

For every case, the research pharmacist evaluated and recorded the appropriateness of antimicrobial treatment following a methodology proposed and validated by the members of the coordinating committee of the SEFH's AFinf Working Group (Pharmaceutical Care of Patients with Infectious Diseases)<sup>20</sup> (Table 1), and derived from on a series of indicators of hospital-based antimicrobial quality described in the literature<sup>21,22</sup>.

### Evaluation method

Each antimicrobial prescription was evaluated by filling in a form that included the items of indications of antimicrobial treatment, antimicrobial agents selected, time of administration of the first dose, dose and frequency of administration, route of administration, duration of treatment, monitoring of efficacy and adverse effects, and completeness of medical record entries. Each item was scored by the research pharmacist of each hospital according to the guidelines provided in table 1.

The evaluation was performed cross-sectionally, rather than longitudinally, in all items except for the duration of treatment, where a retrospective assessment was made once the antimicrobial treatment has been completed. A specific point was made to carry out the evaluation on the same day as the cut-off and, failing that, on the days immediately following, so that the evaluator would have the same clinical and microbiological information as the prescriber.

#### Prescription assessment criteria

Overall, prescriptions were considered appropriate if they were assessed as appropriate across all items (medical records fully completed); suboptimal if they were considered appropriate or suboptimal across all items (adequate or too long in duration of treatment and it did not affect if medical record entries were complete or incomplete); and inappropriate if it was so assessed in any item (too short in duration of treatment).

**Table 1.** AFinf method of prescription evaluation

<b>Indication of the antimicrobial treatment</b>	
<b>Appropriate</b>	The patient has a confirmed bacterial, fungal, or viral infection or is reasonably likely to have one. Surgical or medical antimicrobial prophylaxis is indicated.
<b>Inappropriate</b>	The patient does not have a confirmed bacterial, fungal or viral infection and is not likely to have one. Surgical or medical antimicrobial prophylaxis is not indicated.
<b>Doubtful</b>	I have doubts/I do not have enough evidence to make an informed decision.
<b>Selection of the antimicrobial agent</b>	
<b>Appropriate</b>	The antimicrobial agent is the one of choice according to local protocols or guidelines or failing that, in national or international guidelines or failing that, at the discretion of the observer.
<b>Suboptimal</b>	Although more appropriate alternatives exist, the prescribed agent has been shown to be effective in resolve or preventing the infection.
<b>Inappropriate</b>	The antimicrobial agent is contraindicated or is incapable of resolve or preventing the infection.
<b>Doubtful</b>	I have doubts/I do not have enough evidence to make an informed decision.
<b>Time at which the initial dose was administered</b>	
<b>Appropriate</b>	In severe sepsis/septic shock within 1 hour from onset of symptoms. In severe infection, within 6 hours from onset of symptoms or arrival at the hospital. In cases of surgical antibiotic prophylaxis, between 15 and 60 minutes before surgical incision (except in antibiotics with long half-lives or which require long perfusion times).
<b>Inappropriate</b>	None of the previous criteria are met.
<b>Doubtful</b>	I have doubts/I do not have enough evidence to make an informed decision.
<b>Dosing and frequency of administration</b>	
<b>Appropriate</b>	The dose and frequency of administration selected are those recommended by local or reference guidelines and/or are adapted to to the severity of the infection and the patient's status.
<b>Suboptimal</b>	The dose and frequency of administration selected are capable of resolving the infection but their use could lead to minor problems (e.g. unadjusted dose in patients with renal failure with a small tox-icity risk).
<b>Inappropriate</b>	The dose and frequency of administration selected are ineffective for resolving or preventing the infection and/or their use may lead to major problems (e.g. an insufficient dose may be ineffective and an excessive dose may result in higher toxicity...).
<b>Doubtful</b>	I have doubts/I do not have enough evidence to make an informed decision.
<b>Administration route</b>	
<b>Appropriate</b>	The administration route selected is the one recommended by local or reference guidelines and/or is adapted to the severity of the infection and the patient's status.
<b>Suboptimal</b>	The administration route selected is capable of resolving the infection but its use may lead to minor problems (e.g. if a change to the oral route is not made when required).
<b>Inappropriate</b>	The administration route selected is ineffective for resolving or preventing the infection and/or its use may lead to major problems (e.g. using the oral route in a severe infection).
<b>Doubtful</b>	I have doubts/I do not have enough evidence to make an informed decision.
<b>Duration of treatment</b>	
<b>Appropriate</b>	Surgical antibiotic prophylaxis: Single dose or for as long as established in local protocols or guidelines. Treatment: Length of treatment as recommended by local protocols/guidelines or by national/international guidelines; or if it is the right duration in the observer's opinion.
<b>Too long</b>	Duration $\geq$ 50% than recommended.
<b>Too short</b>	Duration $\leq$ 50% than recommended.
<b>Doubtful</b>	I have doubts/I do not have enough evidence to make an informed decision.
<b>Efficacy and safety monitoring</b>	
<b>Appropriate</b>	All the required measures have been taken to control the efficacy and safety of the antimicrobial treatment (e.g., control of fever, leukocytosis and biomarkers if applicable; removal of control blood cultures in bacteremia due to <i>S. aureus</i> ; blood count in treatment with linezolid; serum creatinine in treatment with aminoglycosides and vancomycin ...).
<b>Suboptimal</b>	Not all the required measures have been taken to control the efficacy and safety of antimicrobial treatment, which is associated with a minor risk of therapeutic failure or toxicity.
<b>Inappropriate</b>	Not all the required measures have been taken to control the efficacy and safety of antimicrobial treatment, which is associated with a major risk of therapeutic failure or toxicity.
<b>Doubtful</b>	I have doubts/I do not have enough evidence to make an informed decision.
<b>Completeness of medical record entries</b>	
<b>Complete</b>	The patient's clinical record provides adequate justification of start, changes or discontinuation of antimicrobial treatment.
<b>Incomplete</b>	The patient's clinical record does not provide adequate justification of start, changes or discontinuation of antimicrobial treatment.
<b>Doubtful</b>	I have doubts/I do not have enough evidence to make an informed decision.

If a prescription contained two doubtful items or less, this did not alter its assessment as appropriate, suboptimal or inappropriate, except if the indication for antibiotic therapy and the choice of agent were both doubtful, in which case it was considered unevaluable. If they received three or more doubtful ratings, they were assessed as unevaluable, except for prescriptions assessed as inappropriate (too short in duration of treatment), in which case they were considered inappropriate.

### Data collection

Data were obtained from the patient's medical records and, if necessary, by contacting the prescribing physician.

The variables collected for each participating center were: number of beds, patient census on the cut-off day and number of patients selected who were prescribed at least one antimicrobial agent. The variables collected for each patient were sex, age, clinical unit in charge, and active antimicrobial agent(s). Prescriptions were evaluated according to the criteria in table 1 on a form designed for that purpose.

The data were collected and managed using the REDCap (Research Electronic Data Capture) electronic data capture tools made available by SEFH<sup>23</sup>.

### Ethical considerations

The study was approved by the Ethics Committee for Research into Medicines of Galicia (Promoter's Code: AFI-AMO-2019-01, Registration Code: 2019/258). The committee decided that patients need not be asked to provide their informed consent. The management of each participating

center was prospectively informed about the study design and methodology and all of them agreed to participate. The principal investigators and collaborators were not remunerated for their work. Physicians were personally contacted once their prescribed antimicrobial treatment was reviewed when, in the investigator's view, their prescriptions appeared to have a negative impact on patients.

### Statistical analysis

The data were analyzed using the Statistical Package for the Social Sciences (SPSS) v. 20. Simple descriptive statistics were used to analyze both the prevalence and appropriateness of antimicrobial treatment.

### Results


A total of 103 hospitals participated in the study, distributed heterogeneously throughout the Spanish territory. The composition by hospital size is reflected in figure 1, and shows a distribution that is not proportional to the real one, with a greater weight in the study of larger hospitals.

The prescriptions of 3,568 patients were reviewed, of whom 1,498 (42.0%) received antimicrobials. Of these, 862 (57.5%) were male and median age was 69 years (range: 0-101). A total of 46.6% of these patients were admitted to a medical unit, 31.2% to a surgical unit, 9.9% to a critical care unit, 8.4% to a hemato-oncological unit, 3.1% to a pediatric unit, and 0.8% to other units. Of the patients on antimicrobial therapy, 1,449 (96.7%) received at least one antibiotic, 126 (8.4%) at least one antifungal, and 80 (5.3%) at least one antiviral. The prevalence of the use of the most frequent antimicrobial agents is shown in table 2.

**Table 2.** Prevalence of the use of the most commonly prescribed antimicrobials

Antimicrobial*	Prevalence		Antimicrobial*	Prevalence	
	N	(%)		N	(%)
Amoxicillin-clavulanic acid	258	7.2%	Cloxacillin	19	0.5%
Ceftriaxone	230	6.4%	Gentamycin	19	0.5%
Piperacillin-tazobactam	207	5.8%	Imipenem	17	0.5%
Meropenem	141	4.0%	Voriconazole	17	0.5%
Levofloxacin	117	3.3%	Amikacin	15	0.4%
Cefazoline	106	3.0%	Amphotericin B	15	0.4%
Ciprofloxacin	87	2.4%	Phosphomycin	14	0.4%
Cotrimoxazole	87	2.4%	Teicoplanin	14	0.4%
Linezolid	75	2.1%	Anidulafungin	13	0.4%
Vancomycin	64	1.8%	Colistimethate	13	0.4%
Fluconazole	62	1.7%	Posaconazole	13	0.4%
Metronidazole	47	1.3%	Cefepime	12	0.3%
Acyclovir	45	1.3%	Ganciclovir	11	0.3%
Daptomycin	38	1.1%	Remdesivir	11	0.3%
Azithromycin	34	1.0%	Cefotaxime	10	0.3%
Cefuroxime	34	1.0%	Ceftazidime-avibactam	10	0.3%
Ertapenem	30	0.8%	Aztreonam	9	0.3%
Ampicillin	26	0.7%	Caspofungin	9	0.3%
Clindamycin	26	0.7%	Valganciclovir	8	0.2%
Ceftazidime	21	0.6%	Ceftaroline	7	0.2%

\*Includes oral, parenteral and inhaled routes of administration.

**Figure 1.** Distribution and size of participating hospitals.

\*Source: 2019 Spanish Hospital Catalog. Ministry of Health, Consumer Affairs and Social Welfare.

Of the patients who received antimicrobial therapy, 424 (28.3%) did so in combination therapy; 358 (23.9%) received at least two antibiotics and 120 patients (8.0%) were treated with a combination of a  $\beta$ -lactam active against *Pseudomonas aeruginosa* and an agent active against methicillin-resistant *Staphylococcus aureus*.

Regarding the appropriateness of treatment, the prescription was considered appropriate in 34% of the cases, suboptimal in 45%, inappropriate in 19% and unevaluable in 2% (Table 3).

The items that most influenced assess a prescription as suboptimal were completeness of medical record entries, type of antimicrobial agent selected, duration of treatment and monitoring of efficacy and safety. In 21% of cases where the prescription was assessed as suboptimal, the only reason was incompleteness of data in the patient's medical record (in 79% of the remaining cases, several items converged). The item that most influenced rating a prescription as inappropriate was the indication of antimicrobial

treatment, with the antimicrobial being considered unnecessary in 8% of prescriptions.

## Discussion

PAUSATE is the first nationwide study in Spain to simultaneously measure the prevalence and appropriateness of the hospital use of antimicrobials by means of a prevalence survey.

The prevalence data obtained in the PAUSATE study are similar to those in the latest RENAWE survey in 2019<sup>15</sup>. Thus, in the PAUSATE study 42% of the patients were receiving at least one antimicrobial, as compared to 45.8% in the RENAWE survey. It should be considered, however, that both studies differ in the composition of the ATC groups analyzed. Indeed, the RENAWE study, unlike the PAUSATE study, included ATC groups A07 and P01 and excluded groups J04 (except for agents used for non-tuberculous bacteria) and J05, although these groups include agents with a small impact on consumption (the prevalence of each group is less than 2.5%). In the PAUSATE study, 28.3% of patients who received antimicrobials did so in combination therapy, as compared to 27.7% in the RENAWE survey.

Of the 10 most highly consumed antimicrobials in the PAUSATE study, nine were the same as in the RENAWE survey, with virtually identical positions. However, the use of broad-spectrum antimicrobials such as piperacillin-tazobactam, meropenem and linezolid was slightly higher in the PAUSATE study than in the RENAWE survey (5.8%, 4.0% and 2.1% vs. 5.2%, 3.5% and 1.8% respectively). Other antimicrobials such as amoxicillin-clavulanic acid, levofloxacin, cefazolin, and ciprofloxacin were more commonly used in the RENAWE survey than in the PAUSATE study (8.9%, 4.9%, 4.6% and 2.9% vs. 7.2%, 3.3%, 3.0% and 2.4%, respectively), which is consistent with the greater proportion of larger hospitals included in the PAUSATE study. Such hospitals tend to treat cases of greater complexity and usually exhibit higher incidences of nosocomial infections and resistant microorganisms.

Other findings resulting from the higher proportion of larger hospitals in the PAUSATE study include a higher prevalence of antifungals as compared to RENAWE (8.4% vs. 3.7%) and a higher percentage of patients on a combination of a  $\beta$ -lactam active against *Pseudomonas aeruginosa* with an agent active against methicillin-resistant *Staphylococcus aureus* (8.0%).

Unlike the RENAWE survey, the PAUSATE study was limited to collecting data on the prevalence and appropriateness of the use of antimicrobials, without gathering information on the indication for antimicrobials (prophylaxis, empirical or targeted therapy, or community or nosocomial infection) or patient-related risk factors (comorbidities, immunosuppression, devices and implants, etc.).

**Table 3.** Appropriateness by item and overall prescription

Item	Appropriateness (%)			
	Appropriate	Suboptimal	Inappropriate	Doubtful
Indication of an antimicrobial	88%		8%	4%
Agent selection	71%	23%	3%	3%
Time at which the initial dose was administered	86%		6%	8%
Dosing and frequency of administration	87%	7%	4%	2%
Administration route	89%	9%	1%	1%
Duration of treatment	69%	19%	2%	10%
Efficacy and safety monitoring	75%	17%	4%	4%
Completeness of medical record entries	53%		34%	13%
<b>Overall prescription</b>	<b>34%</b>	<b>45%</b>	<b>19%</b>	<b>2%</b>



The National Plan against Antibiotic Resistance (PRAN) of the Spanish Agency for Medicines and Health Products describes the levels of consumption of antimicrobials in Spanish hospitals, expressed as the number of Defined Daily Doses per 1,000 inhabitants per day<sup>24</sup>. Although these values cannot be compared directly with the prevalence data of the PAUSATE study as both the methodology and the units of measurement used are different, it can be seen that four of the five most commonly consumed antibiotics in the PRAN coincide in those reported in the PAUSATE prevalence study.

The international literature reports that between 16% and 70% of antimicrobial treatments are inappropriate. However, most of the data comes from low-quality studies characterized by very heterogeneous designs and methodologies. In Spain, a few studies were published that reveal the high levels of inappropriateness antimicrobial use in the country's hospitals, but they are either single-center or refer to specific areas of hospitalization<sup>25,27</sup>.

The main problem with assessing the quality of antimicrobial use is that there is no standardized evaluation method that covers all the different items of antimicrobial prescribing and that defines the scale of each of these items and by extension the qualification of the prescription as a whole.

A further critical point in the evaluation of antimicrobial prescribing is inter-observer variability. Subjectivity in the evaluation of antimicrobial prescribing is a consequence of the uncertainties inherent in many cases in the approach to infectious disease and the management of antibiotic therapy.

In order to minimize these aspects in the PAUSATE study, the AFInf group designed a method based on an evaluation form with specific and objective records related to local guidelines or, in their absence, to national or international reference guidelines. The form was put together by a group of pharmacists with long experience in the care of patients with infectious diseases who, in many cases, were members of their hospitals' antibiotic stewardship teams.

The PAUSATE study showed that 45% of antimicrobial prescriptions were suboptimal and 19% were inappropriate.

In the analysis by items, the one with the greatest room for improvement was completeness of medical record entries, with entries being incomplete in 34% of prescriptions. This item was not considered crucial enough to assess the whole prescription as inappropriate, but it was the reason why one out of every five prescriptions were assessed as suboptimal rather than appropriate.

Documenting the clinical management plan, as well as reflecting the antimicrobial treatment selected together with its indication and the duration of treatment are recommendations included in stewardship programs<sup>21,28</sup>. Explicitly stating an antibiotic plan in the patients' medical record helps physicians reflect on the decisions made and facilitates the review of antibiotic treatment.

The choice of antimicrobial agent was suboptimal in 23% and inappropriate in 3% of the prescriptions evaluated. A suboptimal assessment indicated non-adherence to reference protocols or guidelines or the use of equally effective but less safe, ecological, or inexpensive therapeutic alternatives. An inappropriate assessment refers to a larger issue of ineffectiveness or safety of the prescribed agent.

Other items with less favorable results were the duration of treatment (excessive in 19% of cases and too short in 2%) and the monitoring of efficacy and safety (suboptimal in 17% of cases and inappropriate in 4%).

The most concerning result of the study was the considerable percentage of prescriptions classified as inappropriate (19%), i.e., those where, in the evaluator's opinion, the patient did not require an antimicrobial, or its use did not guarantee the patient's cure or caused unacceptable harm. This data reinforces the need to implement measures to optimize the use of antimicrobials.

This study presents with several limitations. Firstly, the voluntary participation of the centers, apart from providing a heterogeneous distribution that is not representative of reality, with a disproportionately high participation of larger hospitals, can lead to a selection bias as it could be argued that the centers participating in the study were those most keen on optimizing the use of antimicrobials. Another selection bias is that the study sample only included patients who received at least one antimicrobial, excluding those who did not receive an antimicrobial although they required it (default antimicrobial indications were not analyzed).

Another limitation of the study is seasonality. The use of antimicrobials varies between different times of the year. The PAUSATE study was carried out in the month of April and overlapped with the RENAVE survey, which collected its data in May. Another factor that could distort the data obtained on antimicrobial use is the presence of patients admitted with SARS-CoV-2 pneumonia. During the data collection period, the percentage of hospital beds occupied by patients with SARS-CoV-2 infection ranged between 6.4% and 8.2%<sup>29</sup>.

The fact that the study was conducted by hospital pharmacists could have constituted an observer bias. Evaluation of antimicrobial prescriptions is assumed to be subject to nuances dependent on the observer's judgment. The influence of the observer's academic background in his evaluation of antimicrobial prescriptions was not studied. A forthcoming study, to be published as an extension of the present one, will measure the concordance of assessments by pharmacists and physicians using the AFInf method.

In short, the PAUSATE study provides updated data on the prevalence of the use of antimicrobials in Spanish hospitals. The data obtained are consistent with those previously published in the RENAVE survey and those reported by the PRAN Plan. Moreover, the study is the first of its kind to evaluate appropriateness of antimicrobial use, contemplating all the items in antimicrobial prescribing. An understanding of the prevalence and appropriateness of antimicrobial use is the first step for designing and undertaking the measures required to improve and measuring the impact of implementing antimicrobials within the framework of antimicrobial stewardship plans.

## Funding

No funding was received for this research. The authors and investigators, and their collaborators, received no remuneration for participating in this study.

## Acknowledgements

The authors would like to thank the researchers and other professionals involved in the collection of the data. Their names are contained in a specific section.

## Conflict of interests

The authors have declared no conflict of interest with respect to this research.

## Contribution to the scientific literature

PAUSATE is a nationwide study aimed at measuring the prevalence and appropriateness of antimicrobials use in hospitals.

The results of the study should subsequently be used to design actions geared towards improving antimicrobial stewardship programs.

## Appendix 1. Participating and collaborating hospitals

Complejo Hospitalario Universitario A Coruña	José María Gutiérrez Urbón
Hospital Público de Monforte de Lemos	Laura Villaverde Piñeiro
Complejo Hospitalario Universitario de Vigo	Antonio Pérez Landeiro Nerea García Beloso
Complejo Hospitalario Universitario de Ourense	María del Pilar Rodríguez Rodríguez

**Appendix 1 (cont.).** Participating and collaborating hospitals

Hospital Universitario Lucus Augusti	Ana López-Vizcaíno Castro Alfonso Martínez Portela
Complejo Hospitalario Universitario de Ferrol	Belén Bardán García Ana María Montero Hernández
Hospital Público da Mariña	Yveth Michelle Tajés González Concepción Castro Rubiños
Hospital Público Virxe da Xunqueira	José Luis Rodríguez Sánchez
Complejo Hospitalario Universitario de Pontevedra	Patricia Iglesias Neiro Carlos Crespo Diz Claudia Barca Díez
Complejo Hospitalario Universitario Santiago de Compostela	María Teresa Rodríguez Jato
Hospital del Mar	Daniel Echeverría Esnal Santiago Grau Cerrato
Hospital San Agustín de Linares	María Rosa Cantudo Cuenca
Hospital General Universitario Gregorio Marañón	Carmen Guadalupe Rodríguez González Esther Chamorro de Vega
Hospital Vega Baja Orihuela	Carlos Devesa Garcia Gabriel Martínez Orea
Hospital de Molina	Francisco de Asís López Guerrero Gonzalo Fernández Campuzano
Hospital Morales Meseguer	Dolores Nájera Pérez Lydia Fructuoso
Hospital de Figueres	Virginia Gol Vallés
Hospital Universitari General de Catalunya	María Pilar Marcos Pascua
Hospital General Mancha Centro	M <sup>o</sup> Carmen Conde García
Hospital General Universitario de Ciudad Real	Raúl Pérez Serrano Patricia Nieto-Sandoval Martín de la Sierra Belén Mayo Canalejo
Hospital universitari Son Espases	Leonor del Mar Periañez Parraga
Hospital Universitario de Cabueñes	Sonia Tembrás Martínez Rubén Pampín Sánchez
Hospital de Barcelona	Ana Ayestarán
Hospital Universitario 12 de Octubre	José Manuel Caro Teller Sara Ortíz Pérez
Hospital Universitario Torrejón de Ardoz	Guadalupe Sevilla Santos
Hospital de Sant Joan de Déu	María Goretti López Ramos
Hospital Clínico de Salamanca	Ana López González Marcos Martín Gil Diego Peña Lorenzo
Sanatorio Sagrado Corazón de Valladolid	Antonio Martín González
Hospital Universitario Santa Cristina	Iratxe Marquínez Alonso
Consorcio Hospital General Universitario de Valencia	María Pilar Ortega García Pablo Pérez Villalón Marta Zaragoza Rodríguez
Hospital Fundació Esperit Sant	Núria Miserachs Aranda
Hospital Universitari de Bellvitge	Ariadna Padullés Zamora Iria Varela Rey Pol Cleeries Rovira
Complejo Hospitalario Universitario de Albacete	Cristina García Gómez Eduardo Tébar Martínez Héctor Alabort Ayllon Juan Manuel Collado Sanz Sonia Ruiz Sánchez Belén Serna Serrano Cristina del Pozo Carlavilla Manuel Clemente Andújar Sergio Planta Paniagua María Rosa Ortiz Navarro José Luis Sánchez Serrano

**Appendix 1 (cont.).** Participating and collaborating hospitals

Hospital Universitari i Politècnic La Fe	Tomás Palanques Pastor Eva Romá Sánchez Hugo Ribes Artero Mireya Fernández Sánchez Eduardo Guerrero Hurtado
Hospital Universitario Virgen del Rocío	Marta Mejías Trueba María Victoria Gil Navarro Marta Alonso Moreno
Institut Català d'Oncologia Badalona	Cristina Ibáñez Collado María Alcalde Rodrigo
Hospital Torrecárdenas	Eduardo Tejedor Tejada Pablo Nieto Guindo
Hospital Can Misses	Fernando Becerril Moreno Lidia Comendador Martínez
Hospital QuironSalud Sagrado Corazón	Ángel Albacete Ramírez
Hospital Universitario de Jaén	Isabel Caba Porras Rocío Contreras Collado Lucía Gutiérrez Lucena Trinidad Vilchez Medina
Hospital Sagrat Cor Barcelona	Neus Pons Llobet Marina de Temple Plá
Complejo Asistencial Universitario de León	Mónica Sáez Villafañe
Fundacion Hospital de Avilés	Paula Raviña Fernández
Hospital La Pedrera	Amparo Navarro Catalá
Hospital Universitario de La Ribera	Paula García Llopis
Hospital Universitario de Jerez	María Teresa Gómez de Travededo y Calvo José Carlos Roldán Morales Valle Sánchez-Matamoros Piazza
Hospital Clínico San Carlos	Rocío Manzano Lorenzo Lidia Ybáñez García
Hospital Universitario de Móstoles	Noelia Garrido Peño Carmen Moriel Sánchez
Hospital de la Vega Lorenzo Guirao	Inmaculada Sánchez Martínez María Muros Ortega Francisco Valiente Borrego
Hospital General Universitario Reina Sofía	Carmen Caballero Requejo Alba María Martínez Soto
Hospital Monte Naranco	Adrián Rodríguez Ferreras Antonia Candás Villar
Hospital Arnau de Vilanova-Lliria	María Inmaculada Seguí Gregori Ainhoa Saera Serrano Lucía Santiago Martínez
Hospital Puerta de Hierro	Marina Calvo Salvador Inés Gumiel Baena Raquel Sanabrias Fernández de Sevilla María Dolores García Cerezuela Amelia Sánchez Guerrero
Complejo Asistencial de Zamora	José Jiménez Casaus Álvaro Corral Alaejos Inés Gil Navarro José Sebastián Roldán González Carmen Gil Valiño Sonia Fernández Cañabate Guillermo Goda Montijano Marisa Paredes Bernaldo de Quirós Juan Carlos Herrezuelo Castellanos María Dolores Alonso Castañé
Complejo Hospitalario de Puerto Real	Marcelo Domínguez Cantero Carmen María Domínguez Santana
Hospital El Bierzo	Julio Antonio Valdueza Beneitez



**Appendix 1 (cont.).** Participating and collaborating hospitals

Hospital Universitario La Paz	Francisco Moreno Ramos
Hospital de Hellín	Gregorio Romero Candel
Hospital General Universitario de Elche	Carmen Matoses Chirivella Alicia Rochina Astorga Gemma Miralles Andreu
Hospital Germans Trias i Pujol	Marlene Álvarez Martins Lydia Carabias Ané Adrián Vilarino Seijas Carles Quiñones Ribas
Hospital Universitario Donostia	Miren Ercilla Liceaga
Hospital Universitario Miguel Servet	Rafael Huarte Lacunza María Pilar Olier Martínez Andrea Pinilla Rello
Hospital Universitario de Igualada	Joan Serrais Alexandra Retamero
Hospital Universitario Príncipe de Asturias	Gema Baldominos Utrilla Inés Fernández Cebrecos Nerea Fernández Arberas
Hospital QuirónSalud Albacete	Marca Díaz Rangel Emilio José Sevilla Ana Martínez López
Hospital Quirón Barcelona	Diego Mena Carmona Rocío Gil Partal
Hospital General Universitario Castellón	María Dolores Bellés Medall Teresa Cebolla Beltrán María Santos San Segundo
Clínica IMQ Zorrotzaurre	Cristina Garay Sarría
Hospital Comarcal d'Inca	María Jaume Gaya
Hospital Universitario Virgen de la Victoria	Elena Sánchez Yáñez
Hospital Universitario Vall d'Hebron	Ignacio Cardona David Company Herrero
Hospital Universitario Virgen Macarena	Margarita Beltrán García Alicia Aguado Paredes Laura Moñino Domínguez Cristina Castillo Martín Ariana Martínez Suárez Marta Valera Rubio Marisa Moya Martín Santiago Sandoval Fernández del Castillo
Hospital Fremap de Majadahonda	Aixa Fernández Estalella
Hospital Universitario San Juan de Alicante	Rosa María Provencio Arranz Laura Barraión Pérez Juan Campillo López Anais González López
Hospital San Vicente del Raspeig	Lorena Pascual Ramírez María Josefa Cortés Botella
Hospital Universitario Mutua Terrassa	Núria Sanmartí Martínez
Hospital Virgen del Mar	Sonia Cruz Pardos Pilar Angustias Martínez Ortega Elena Rodríguez del Río
Hospital Puerta del Mar	María Eugenia Rodríguez Mateos
Hospital Universitario de Burgos	Marta Ubeira Iglesias Sara Arnáiz Díez Ana Infante Camarero María de Frutos del Pozo
Fundació Hospital Sant Joan de Déu de Martorell	Marta Martí Navarro
Hospital San Eloy	Jaione Bilbao Aguirregomezorta
Clinica La Asunción	Borja Ollo Tejero

**Appendix 1 (cont.).** Participating and collaborating hospitals

Hospital Universitario la Princesa	María de los Desamparados Ibáñez Zurriaga Esther Ramírez Herráiz
Hospital de la Santa Creu i Sant Pau	Edurne Fernández de Gamarra Martínez Jesús Ruiz Ramos
Hospital Universitario Basurto	José Antonio Domínguez Menéndez
Hospital Alto Deba	Lorea Arteche Eguizabal Ainhoa Urrutia Losada Saioa Domingo Echaburu
Hospital Urduliz	Eguzkiñe Ibarra García
Hospital Universitario Infanta Elena	Virginia Collados Arroyo Rosalía Fernández Caballero Araceli Henares López Carmen Mayo López
Hospital General de Valdepeñas	Palmira Quero González Pelayo Nieto Gómez
Hospital Clínico Lozano Blesa	Mercedes Arenere Mendoza Jose Manuel Vinuesa Hernando Beatriz Bonaga Serrano
Hospital Universitario Joan XXIII	María Mendoza Aguilera Pilar Ana López Broseta María Ángeles Roch Ventura Erika Esteve Pitarch Laura Canadell Vilarrasa
Organización Sanitaria Integrada Bidasoa	María Idoia Michelena Hernández
Hospital Santa Marina	Joana González Arnáiz
Hospital Universitario Cruces	Mikel Castaño López Beatriz Baza Martínez Beatriz Baza Martínez
Hospital General de Villarrobledo	Ana Isabel Fernández Marchante Nuria Monteagudo Martínez Ismael Pérez Alpuente María Jose de Mora Alfaro Eva Garcia Martínez
Hospital General de Almansa	Ana Ramirez Corcoles José Marco del Río
Hospital Universitario Infanta Cristina	Miguel Ángel Amor García
Hospital San Rafael	María José Fraile Inés Gozalo Nadia Méndez Sandra Gracia
Corporació Sanitària Parc Taulí	Sara Ortonobes Roig
Hospital Universitario Dr. Josep Trueta	Cristina Díez Vallejo Cristina Toro Blanch Anna Fayet Pérez
Hospital Carmen y Severo Ochoa	Miguel Lamas López Miguel Al-kassam Martínez
Clínica Universidad de Navarra	Irene Aquerreta González
Hospital QuirónSalud Santa Cristina de Albacete	Marca Díaz Rangel Emilio José Sevilla Ana Martínez López

**Bibliography**

1. Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2019: third Australian report on antimicrobial use and resistance in human health [Internet]. Sydney: ACSQHC; 2019 [accessed 12/28/2021]. Available at: <https://www.safetyandquality.gov.au/our-work/antimicrobial-resistance/antimicrobial-use-and-resistance-australia-surveillance-system-aura/aura-2019>
2. Cusini A, Rampini SK, Bansal V, Ledergerber B, Kuster SP, Ruef CH, *et al.* Different Patterns of Inappropriate Antimicrobial Use in Surgical and Medical Units at a Tertiary Care Hospital in Switzerland: A Prevalence Survey. *PLoS ONE*. 2010;5(11):e14011. DOI: 10.1371/journal.pone.0014011
3. Willemsen I, Van der Kooij T, Van Benthem B, Wille J, Kluytmans J. Appropriateness of antimicrobial therapy: a multicentre prevalence survey in the Netherlands, 2008-2009. *Euro Surveill*. 2010;15(46):19715. DOI: 10.2807/es.e15.46.19715-en
4. Saleem Z, Saeed H, Hassali MA, Godman B, Asif U, Yousaf M, *et al.* Pattern of inappropriate antibiotic use among hospitalized patients in Pakistan: a longitudinal

- surveillance and implications. *Antimicrob Resist Infect Control*. 2019;8:188. DOI: 10.1186/s13756-019-0649-5
5. Shaughnessy MK, Amundson WH, Kuskowski MA, Decarolis DD, Johnson JR, Drekonja DM. Unnecessary antimicrobial use in patients with current or recent *Clostridium difficile* infection. *Infect Control Hosp Epidemiol*. 2013;34:109-16. DOI: 10.1086/669089
  6. Fraser A, Paul M, Almasreh N, Tacconelli E, Frank U, Cauda R, *et al*. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. *Am J Med*. 2006;119:970-6. DOI: 10.1016/j.amjmed.2006.03.034
  7. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, *et al*. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest*. 2009;136:1237-48. DOI: 10.1378/chest.09-0087
  8. WHO. Global Action Plan on Antimicrobial Resistance [Internet]. Geneva: World Health Organization; 2015 [Internet] [accessed 12/28/2021]. Available at: <https://www.who.int/publications/i/item/global-action-plan-on-antimicrobial-resistance>
  9. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, *et al*. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis*. 2016;62(10):e51-77. DOI: 10.1093/cid/ciw118
  10. Rodríguez-Baño J, Paño-Pardo JR, Álvarez-Rocha L, Asensio Á, Calbo E, Cercenado E, *et al*. Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSH consensus document. *Farm Hosp*. 2012;36(1):33.e1-30. DOI: 10.1016/j.farma.2011.10.001
  11. Coenen S, Ferech M, Haaijer-Ruskamp FM, Butler CC, Vander Stichele RH, Verheij TJ, *et al*. European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. *Qual Saf Health Care*. 2007;16(6):440-5. DOI: 10.1136/qshc.2006.021121
  12. Gutiérrez-Urbón JM, Gil-Navarro MV, Moreno-Ramos F, Núñez-Núñez M, Paño-Pardo JR, Perriáñez-Párraga L. Indicadores del uso hospitalario de antimicrobianos basados en el consumo. *Farm Hosp*. 2019;43(3):94-100. DOI: 10.7399/fh.11163
  13. Versporten A, Zarb P, Caniaux I, Gros MC, Drapier N, Miller M, *et al*, en representación del Global-PPS network. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. *Lancet Glob Health*. 2018;6(6):e619-29. DOI: 10.1016/S2214-109X(18)30186-4
  14. Osowicki J, Gwee A, Noronha J, Britton PN, Isaacs D, Lai TB, *et al*. Australia-wide Point Prevalence Survey of Antimicrobial Prescribing in Neonatal Units: How Much and How Good? *Pediatr Infect Dis J*. 2015;34(8):e185-90. DOI: 10.1097/INF.0000000000000719
  15. Informe de vigilancia 2018-2019. Encuesta de prevalencia de las IRAS y uso de antimicrobianos en los hospitales de España. Unidad de Vigilancia de las Infecciones Relacionadas con la Asistencia Sanitaria. Centro Nacional de Epidemiología (CNE). Instituto de Salud Carlos III (ISCIII). Madrid, España; 2021.
  16. DePestel DD, Eiland EH, Lusardi K, Destache CJ, Mercier RC, McDanel PM, *et al*. Assessing appropriateness of antimicrobial therapy: in the eye of the interpreter. *Clin Infect Dis*. 2014;59 Suppl 3:S154-61. DOI: 10.1093/cid/ciu548
  17. Retamar P, Martín ML, Molina J, Del Arco A. Evaluating the quality of antimicrobial prescribing: is standardisation possible? *Enferm Infecc Microbiol Clin*. 2013;31 Suppl 4:25-30. DOI: 10.1016/S0213-005X(13)70129-0
  18. Spivak ES, Cosgrove SE, Srinivasan A. Measuring Appropriate Antimicrobial Use: Attempts at Opening the Black Box. *Clin Infect Dis*. 2016;63(12):1639-44. DOI: 10.1093/cid/ciw658
  19. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs, 2021. Oslo, Norway; 2020 [Internet] [accessed 12/28/2021]. Available at: [https://www.whocc.no/atc\\_ddd\\_index\\_and\\_guidelines/atc\\_ddd\\_index/](https://www.whocc.no/atc_ddd_index_and_guidelines/atc_ddd_index/)
  20. Gutiérrez-Urbón JM, y miembros del Grupo de Atención Farmacéutica al Paciente con enfermedad Infecciosa de la Sociedad Española de Farmacia Hospitalaria. Diseño y validación de la metodología AFin de evaluación de las prescripciones hospitalarias de antimicrobianos [póster]. Libro de comunicaciones. 66.º Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria. A Coruña; 18-21 octubre 2021; p. 504.
  21. Van den Bosch CMA, Geerlings SE, Natsch S, Prins JM, Hulscher MEJL. Quality indicators to measure appropriate antibiotic use in hospitalized adults. *Clin Infect Dis*. 2015;60(2):281-91. DOI: 10.1093/cid/ciu747
  22. Kallen MC, Prins JM. A systematic review of quality indicators for appropriate antibiotic use in hospitalized adult patients. *Infect Dis Rep*. 2017;9(1):6821. DOI: 10.4081/idr.2017.6821
  23. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, *et al*; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. 2019;95:103208. DOI: 10.1016/j.jbi.2019.103208
  24. Plan Nacional Resistencia Antibióticos. Consumo de Antibióticos en Hospitales [Internet]. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS); 2021 [accessed 01/15/2022]. Available at: <http://www.resistenciaantibioticos.es/es/profesionales/vigilancia/mapas-de-consumo>
  25. Osorio G, Fresco L, Monclús E, Carbó M, Ortega M. Adecuación del uso de antibióticos de "Categoría Especial" en el Servicio de Urgencias de un hospital de tercer nivel. *Rev Esp Quimioter*. 2020;33(1):24-31. DOI: 10.37201/req/066.2019
  26. Pareja Rodríguez de Vera A, García Vázquez E, Hernández-Torres A, Yagüe Guirrao G, Almanchel Rivadeneira M, De la Rubia Nieto A, *et al*. Evaluación de la adecuación del uso de antimicrobianos en un hospital de tercer nivel: Estudio Preliminar a la implantación de un Programa de Optimización del Uso de Antimicrobianos (PROA). *Rev Clin Esp*. 2014;214 [Esp Congr]:51.
  27. Suberviola Cañas B, Jáuregui R, Ballesteros MÁ, Leizaola O, González-Castro A, Castellanos-Ortega A. Effects of antibiotic administration delay and inadequacy upon the survival of septic shock patients. *Med Intensiva*. 2015;39(8):459-66. DOI: 10.1016/j.medin.2014.12.006
  28. National Institute for Health and Care Excellence. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use [Internet]. 2015 [accessed 12/28/2021]. Available at: <https://www.nice.org.uk/guidance/ng15>
  29. Actualización de la enfermedad por el coronavirus (COVID-19). Situación en España. Centro de Coordinación de Alertas y Emergencias Sanitarias. Dirección General de Salud Pública. Ministerio de Sanidad. [Internet] [accessed 12/28/2021]. Available at: [https://www.mscbs.gob.es/en/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion\\_365\\_COVID-19.pdf](https://www.mscbs.gob.es/en/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_365_COVID-19.pdf)